Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 3, 1999, Pages 779-783

  Merbs, Shannath L ^a   Sidransky, David ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ARTICLE; GENE DELETION; GENE LOCUS; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MELANOMA; METHYLATION; MOLECULAR GENETICS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; UVEA TUMOR; X CHROMOSOME INACTIVATION;

CHROMOSOMES, HUMAN, PAIR 16; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; GENE DELETION; GENES, P16; HUMANS; LOSS OF HETEROZYGOSITY; MELANOMA; MICROSATELLITE REPEATS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; UVEAL NEOPLASMS;

EID: 0032978249     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Scotto J, Fraumeni JF, Lee JAH. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst. 1976;56:489-491.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
3. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
4. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germ-line mutations in familial melanoma. Nat Genet. 1994;8:15-21.
5. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
6. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS-1) mutations in primary tumors with 9p loss. Science. 1994;265:415-416.
7. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary tumours. Nat Genet. 1995;11: 210-212.
8. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1:686-692.
9. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa J-P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
10. Bird A. The essentials of DNA methylation. Cell. 1992;70:5-8.
11. Migeon BR. Insights into X chromosome inactivation from studies of species variation, DNA methylation and replication, and vice versa Genet Res. 1990;56:91-98.
12. Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993;366:362-365.
13. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525-4530.
14. Reed AL, Califano J, Cairns P, et al. High Frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996;56:3630-3633.
15. Singh AD Croce CM, Wary KK, et al. Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). Ophthalmic Genet. 1996;17:39-40.
16. Speicher MR, Prescher G, du Manoir S, et al. Chromosomal gains and losses in uveal melanoma detected by comparative genomic hybridization. Cancer Res. 1994;54:3817-3823.
17. Ohta M, Berd D, Shimizu M, et al. Deletion mapping of chromo some region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer 1996;65:762-767.
18. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type and enucleation as risk factors in metastasis. Hum Pathol. 1983;13:123-132.
19. van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res. 1994;54:1156-1158.
20. Okami K, Cairns P, Westra WH, et al. Detained deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. Int J Cancer. 1997;74:588-592.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specinc PCR: a novel PCR assay for methylation status of CpC islands. Proc Natl Acad Sci. 1996;93:9821-9826.
22. Liggett WH Jr. Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res. 1996;56: 4119-4123.
23. Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase inhibitor gene. CDK4I, in melanoma. Cancer Res. 1994;54:5269-5272.
24. Jensen OA. Malignant melanoma of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol. 1981; 60:161-162.
25. Green MH, Fraumeni JF Jr. The Hereditary Variant of Malignant Melanoma. New York: Grune & Straton: 1979.
26. Singh AD, Shields CL, De Potter P, et al. Familial uveal melanoma. Arch Ophthalmol. 1996;114:392-399.
27. Singh AD, Donoso LA, Jackson L, Shields CL, De Potter P, Shields JA. Familial uveal melanoma: absence of constitutional cytogenetic abnormalities in 14 cases. Arch Ophthalmol. 1996;114:502-503.
28. Singh AD, Croce CM, Wary KK, et al. Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). Ophthalmic Genet. 1996;17:39-40.
29. Singh AD, Wang MX, Donoso LA, Shields CL, De Potter P, Shields JA. Genetic aspects of uveal melanoma: a brief review. Semin Oncol. 1996;23:768-772.
30. Healy E, Belgaid CE, Takata M, Vahlquist A, Rehman I, Rigby H, Rees JL. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res. 1996;56:589-593.